Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Outlook Therapeutics ( (OTLK) ).
On June 28, 2025, Outlook Therapeutics, Inc. announced the appointment of Robert Charles Jahr as the new President and Chief Executive Officer, effective July 1, 2025. Jahr, who previously held significant roles in Sobi North America and UCB Pharma SA, brings extensive experience in commercial strategy and market access to the company. The appointment also involved an increase in the board size to ten directors, with Jahr filling the new vacancy. The employment agreement includes a base salary, bonus potential, and stock options, with specific severance benefits outlined in the event of a qualifying termination.
The most recent analyst rating on (OTLK) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
Spark’s Take on OTLK Stock
According to Spark, TipRanks’ AI Analyst, OTLK is a Underperform.
Outlook Therapeutics is facing critical financial challenges with no revenue and high leverage, posing substantial risks. The technical analysis shows weak momentum with mixed signals, while the valuation indicates non-profitability. These factors collectively suggest a low stock score.
To see Spark’s full report on OTLK stock, click here.
More about Outlook Therapeutics
Average Trading Volume: 625,250
Technical Sentiment Signal: Sell
Current Market Cap: $68.57M
Learn more about OTLK stock on TipRanks’ Stock Analysis page.